Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD3 | P08294 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16035465 | 0.99 | SOD3 (0.35) | SOD3CREBBPHTR1AHTR2AHTR7 | |
| SCHEMBL16089603 | 0.83 | P2RX7 (0.47) | CREBBPP2RX7 | |
| Hydrochloric Acid SCHEMBL16036462 | 0.82 | P2RX7 (0.46) | CREBBPP2RX7 | |
| SCHEMBL16089630 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL16036233 | 0.77 | — | — | |
| SCHEMBL16089631 | 0.77 | P2RX7 (0.39) | HTR2AHTR7P2RX7 | |
| Hydrochloric Acid SCHEMBL16036430 | 0.75 | P2RX7 (0.38) | SOD3HTR2AHTR7P2RX7 | |
| Hydrochloric Acid SCHEMBL31163291 | 0.74 | HTR2A (0.46) | HTR2A | |
| SCHEMBL16200125 | 0.72 | HTR7 (0.38) | HTR7 | |
| SCHEMBL16088518 | 0.71 | SOD3 (0.36) | SOD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| EP-3495365-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190092770-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| EP-2970267-B3 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-30 | — | — | EP | disclosed |
| EP-3239151-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-11-01 | — | — | EP | disclosed |
| US-9464084-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| US-9464084-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20150322062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-20150322062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-20190092770-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-20160039809-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RX5 | SOD3 4439/4885CREBBP 2668/4885HTR1A 163/4885 |
| US-20150322062-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | SOD3 4403/4885CREBBP 2428/4885HTR1A 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.